Loading data for XFOR — first visit, this takes a few seconds.

Alerta

X4 Pharmaceuticals Inc. (XFOR)

NasdaqCM: XFOR · Precio en tiempo real · USD

4.64

+0.47 (11.27%)

Al cierre: Aug 07, 2026, 8:00 PM

11.27% (1D)

No hay datos disponibles

Precio de compra	4.62
Capitalización de mercado	460.04M
Ingresos (TTM)	9.01M
Beneficio neto (TTM)	-99.72M
Beta	0.39
EPS (TTM)	1.43
Ratio PER (TTM)	3.24
Adelante PE	-5.89
P/B (TTM)	2.26
P/S (TTM)	51.04
Earnings Date	Nov 5, 2026

Precio de venta	5.5
Volumen	1,590,946
Volumen medio (20D)	691,472
Abierto	4.26
Anterior Cerrar	4.17
Rango del día	4.21 - 4.82
Rango de 52 semanas	1.35 - 4.83
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de XFOR

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agre...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Nov 16, 2017

Empleados 45

Bolsa de Valores NasdaqCM

Símbolo bursátil XFOR

Sitio web https://www.x4pharma.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de X4 Pharmaceuticals fueron 35.11M, un aumento de 1,273.21% en comparación con 2.56M del año anterior. Las ganancias fueron -79.2M, un aumento de 111.48%.

Estados financieros

Sorpresa de resultados

X4 Pharmaceuticals ha publicado sus resultados trimestrales en Aug 6, 2026:

Ingresos de $8.81M falla las estimaciones por $0, con 346.33% Crecimiento interanual.

EPS de -0.13 supera las estimaciones en 0.05, con 96.25% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que X4 Pharmaceuticals Inc. publique sus resultados el Nov 5, 2026, durante el horario de mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

1 semana hace · Zacks

X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates

X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +31.58% and +340.30%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1 semana hace · Zacks

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +10.35% and +12.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

3 meses hace · Simply Wall St.

How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress

X4 Pharmaceuticals has seen its modeled fair value price target move from US$8.00 to US$11.67, a sizable uplift that puts more focus on what the current share price is really discounting. Analysts are...

3 meses hace · Zacks

Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now

X4 Pharmaceuticals (XFOR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could...

3 meses hace · Zacks

X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know

X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Página 1 de 2

X4 Pharmaceuticals Inc. (XFOR)